Hyperglycemia can be considered a determining factor in the development of diabetic neuropathy as well as neuropathic pain. There is a relationship between the excessive production of reactive oxygen species (ROS) and the pathogenesis of diabetic neuropathic pain. Taxifolin, on the other hand, is a flavonoid that has been documented to inhibit ROS production. To investigate the effects of taxifolin, which has antioxidant and neuroprotective effects, on alloxan-induced hyperglycemia-induced neuropathy and neuropathic pain, biochemically and histopathologically. The albino Wistar male rats were divided into 3 groups: healthy group (HG), only alloxan group (AXG) and alloxan+taxifolin group (ATG). Hyperglycemia in animals was caused through intraperitoneal injection of alloxan at a dose of 120 mg/kg. Paw pain thresholds of animals were measured using Basile algesimeter. Sciatic nerve tissues were examined biochemically and histopathologically in order to evaluate neuropathy. Our experimental results revealed that taxifolin significantly prevented the increase of plasma glucose concentration level with alloxan administration, the decrease of the paw pain threshold related to hyperglycemia, the change of oxidant-antioxidant balance in the sciatic nerve tissue in favor of oxidants, and the deterioration of tissue morphology in animals. Our experimental results indicate that taxifolin alleviates alloxan-induced hyperglycemia-related neuropathy and neuropathic pain.

For those who helped create the Genki Dama

Background: T-cell lymphomas (TCLs) constitute a heterogeneous group of mature T-cell neoplasms characterized by aggressive clinical behavior and poor outcomes, particularly in the relapsed/refractory (R/R) setting. Belinostat is a pan-HDAC inhibitor approved for R/R peripheral T-cell lymphomas. In this retrospective study, we analyze the real-world outcomes of single-agent belinostat in Turkish patients with R/R TCLs. Methods: Patients with R/R TCLs across Turkey who received at least one course of belinostat were included in the study. The primary end point was the overall response rate (ORR). The secondary end points included progression-free survival (PFS), overall survival (OS) and duration of response (DOR). Results: A total of 59 patients with R/R TCL were enrolled in the study, with a median age of 62 years. The median number of previous lines of therapy before belinostat was 2.5. The ORR for belinostat was 30.5% in the overall study cohort. Response assessment was available in 53 patients, among whom the ORR was 34% (18/53). The median PFS was 3 months. The median OS was 12 months, and the median DOR was not reached in responders. At least one adverse event occurred in 39.0% of patients. Conclusions: Belinostat produced objective responses in a subset of patients. These findings support belinostat as a potential individualized treatment option rather than a broadly effective standard for all patients with R/R TCLs. This multicenter real-world study demonstrates that the observed response rates closely mirror those reported in prospective clinical trials, confirming the reproducibility of belinostat efficacy in routine clinical practice.

Herein, we report a case of appendix adenocarcinoma who presented with a recurrence 8 years after the initial diagnosis. A 54-year-old male underwent appendectomy in 2009. The pathology revealed a 1.7 cm diameter low grade mucinous carcinoid tumor. Any additional treatment was not recommended for patient other than appendectomy. The patient was admitted with the symptoms of ileus at 8 years after surgery and then underwent to right hemicolectomy in 2017. On histopathological examination of the specimen revealed a Goblet cell adenocarcinoid tumor, arising from iliocecal valv with pericolorectal tissue invasion of 5 cm in diameter. Lymph-node metastases were found in 16 dissected lymph nodes. The patient was initiated to treat with combined capecitabine and oxaliplatin chemotherapy. There is no clear evidence to support the superiority of any particular chemotherapy regimen for adjuvant treatment of appendix tumors. In this regard more studies are needed to use combined regimens.